8-K: INmune Bio Advances INKmune Trial in Prostate Cancer, Opens Phase II High Dose Cohort

INmune Bio announces the completion of the Phase I portion of its INKmune trial for metastatic castration-resistant prostate cancer and the opening of the Phase II high dose cohort.

Summary

• INmune Bio Inc. has completed the third and highest dose cohort of the Phase I portion of its INKmune trial for men with metastatic castration-resistant prostate cancer (mCRPC).
• The Scientific Review Committee (SRC) unanimously voted to open all Phase II cohorts of the CaRePC trial to enrollment.
• The company's natural killer cell therapy, INKmune, is being evaluated in a Phase I/II trial.
• Data from the low dose cohort has shown immunologic effects of INKmune therapy.
• The higher dose cohorts will help understand the therapeutic benefits of INKmune therapy in treating men with mCRPC.
• Mark Lowdell, CSO of INMB and inventor of INKmune, will speak at the 10th Annual Innate Killer Summit on March 4th about the use of INKmune to treat men with mCRPC.
• The trial has a Bayesian design with three ascending dose cohorts, and now includes a six patient Phase II extension at the two higher dose levels.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the advancement of the clinical trial and the positive safety data. However, the early stage of the trial and inherent risks in drug development temper the overall sentiment.

Positives

• The completion of the Phase I portion of the INKmune trial and the opening of Phase II is a positive step in the development of the therapy.
• INKmune has demonstrated an exemplary safety profile in the Phase I trial.
• The therapy can be administered in an outpatient setting, improving patient convenience.
• Data from the low dose cohort has shown immunologic effects of INKmune therapy.
• Patient recruitment continues to meet expectations.

Risks

• Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved.
• The company's ability to produce more drug for clinical trials is a risk.
• The availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization is a risk.
• CORDStrom, XPro1595 (XPro), and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved.

Future Outlook

The company plans to continue advancing the INKmune trial in metastatic castration-resistant prostate cancer, with the Phase II high dose cohort now open for enrollment.

Management Comments

• INKmune can be given to men with mCRPC in an out-patient setting and so far has an exemplary safety profile, said RJ Tesi, MD CEO of INmune.
• The higher dose cohorts will help us understand the therapeutic benefits of INKmune therapy in treating men with mCRPC.

Industry Context

The announcement positions INmune Bio within the competitive landscape of companies developing immunotherapies for cancer, particularly those targeting the innate immune system and natural killer cells.

Comparison to Industry Standards

• It is difficult to compare INmune Bio's results directly to industry standards without more detailed clinical data.
• Companies like Fate Therapeutics and Nkarta Therapeutics are also developing NK cell therapies, but their approaches and target indications may differ.
• The success of INKmune will depend on its ability to demonstrate superior efficacy and safety compared to existing treatments and other NK cell therapies in development.

Stakeholder Impact

• Positive news for shareholders as the company advances its clinical program.
• Potential benefit for patients with metastatic castration-resistant prostate cancer if INKmune proves effective.
• Positive for employees of INmune Bio as the company progresses its research and development efforts.

Next Steps

• Enrollment in the Phase II high dose cohort of the INKmune trial will continue.
• Mark Lowdell, CSO of INMB, will present on INKmune at the Innate Killer Summit on March 4th.
• The company will continue to analyze data from the INKmune trial.

Key Dates